SULT1A1 and breast carcinoma: As deletions overlapping SULT1A1 were suggested to decrease breast cancer risk in BRCA1 pathogenic variant carriers, the relative expression of BRCA1 was quantified to assess if the SULT1A1 knockdown affected its regulation (Fig. 3b, Supplementary Data 11).